Signition LP’s Sarepta Therapeutics SRPT Stock Holding History

Signition LP’s Portfolio SRPT Stock Details SRPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-12,368	Closed	-$1.88M	–	155
2019 Q2	$1.88M	Buy	+12,368	New	+$1.5M	1.24%	29

Other funds holding SRPT

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Signition LP's SRPT Position: Q3 2019 in Review

Signition LP sold out of Sarepta Therapeutics (SRPT) in Q3 2019, closing a stake of 12,368 shares — an estimated $1.88M sold.

Signition LP first reported a position in SRPT in Q2 2019 and held it in 1 quarter. The position peaked at $1.88M in Q2 2019. 340 funds tracked by Wall St. Rank hold SRPT as of Q3 2019.

Signition LP reported no remaining Sarepta Therapeutics position as of Q3 2019 after selling out during the quarter.
Signition LP sold 12,368 Sarepta Therapeutics shares in Q3 2019, an estimated $1.88M.
Signition LP first reported a position in Sarepta Therapeutics in Q2 2019 and held it in 1 quarter.
Signition LP's Sarepta Therapeutics position peaked at $1.88M in Q2 2019.
340 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q3 2019.

Based on Signition LP's 13F filing for Q3 2019, filed 5 Nov 2019.